Targeting the Genome-Stability Hub Ctf4 by Stapled-Peptide Design. by Wu, Yuteng et al.
		
	
	
	
	
	
	
Targeting	the	genome	stability	hub	Ctf4	by	stapled-peptide	design	
Yuteng	Wub*,	Fabrizio	Villac*,	Joseph	Mamana*,	Yu	H	Laub,	Lina	Dobnikarb,	Aline	Simona,	Karim	Labibc,	
David	R	Springb,	Luca	Pellegrinia	
a	Department	of	Biochemistry,	University	of	Cambridge,	Sanger	Building,	80	Tennis	Court	Road,	
Cambridge	CB2	1GA,	United	Kingdom	
b	Department	of	Chemistry,	University	of	Cambridge,	Lensfield	Road,	Cambridge	CB2	1EW,	United	
Kingdom	
c	School	of	Life	Sciences,	University	of	Dundee,	Dow	Street,	Dundee	DD1	5EH,	United	Kingdom	
	
	
	
	
	
	
	
*	These	authors	contributed	equally	to	this	manuscript.	
	
For	correspondence:	Karim	Labib	(kpmlabib@dundee.ac.uk),	David	Spring	(spring@ch.cam.ac.uk),	
Luca	Pellegrini	(lp212@cam.ac.uk)	 	
Exploitation	of	synthetic	lethality	by	small-molecule	targeting	of	molecular	pathways	that	maintain	
genomic	stability	has	attracted	much	interest	as	a	chemotherapeutic	tool.	The	Ctf4/AND-1	protein	
factor,	an	evolutionarily	 conserved	hub	 that	 links	DNA	replication,	DNA	repair	and	chromosome	
segregation,	 represents	 in	principle	an	attractive	 target	 for	 the	synthetic	 lethality	approach.	The	
recent	elucidation	of	the	recruitment	mechanism	to	yeast	Ctf4	of	its	protein	partners	has	provided	
a	structural	basis	for	proof-of-principle	development	of	molecular	agents	that	interfere	with	its	hub	
function.	Here	we	report	the	design,	optimization,	biochemical	and	structural	validation	of	double-
click	stapled	peptides	encoding	the	Ctf4-interacting	peptide	(CIP)	motif	of	the	replicative	helicase	
subunit	 GINS	 Sld5.	 By	 screening	 stapling	 positions	 in	 the	 Sld5	 CIP	 sequence,	 we	 identified	 an	
unorthodox	 i,i+6	 stapled	peptide	with	 improved,	 sub-micromolar	 binding	 to	 Ctf4	 relative	 to	 the	
wild-type	CIP.	The	mode	of	interaction	with	Ctf4	was	confirmed	by	a	crystal	structure	of	the	stapled	
Sld5	peptide	bound	to	the	C-terminal	domain	of	Ctf4	(Ctf4CTD).	The	stapled	Sld5	peptide	was	able	to	
displace	the	Ctf4-partner	DNA	polymerase	a	from	the	replisome	in	yeast	extracts.	These	findings	
provide	 experimental	 evidence	 in	 support	 of	 development	 of	 small-molecule	 inhibitors	 of	 the	
human-CTF4	orthologue	AND-1.		
	 	
Introduction	
Targeting	 cancer	 cells	 with	 DNA-damaging	 agents	 such	 as	 cis-platin	 is	 a	 mainstay	 of	 traditional	
chemotherapy,	and	its	effectiveness	might	reflect	the	underlying	fragility	of	cancer	cells	in	maintaining	
their	genomic	stability1.	More	recently,	the	concept	of	synthetic	lethality	as	the	Achilles	heel	of	cancer	
cells	 with	 defective	 pathways	 of	 genome	 stability	 maintenance	 has	 taken	 firm	 hold,	 since	 the	
pioneering	 observations	 that	 breast	 cancer	 susceptibility	 protein	 2	 (BRCA2)-null	 cancer	 cells	 are	
exquisitely	sensitive	to	inhibitors	of	poly(ADP-ribose)	polymerase	(PARP)2,3.	Alongside	DNA-damaging	
agents,	small-molecule	inhibitors	of	proteins	with	essential	roles	in	DNA	synthesis,	such	as	the	DNA	
polymerase	inhibitor	fludarabine4,5	and	topoisomerase	inhibitors	camptothecin	and	etoposide6,7,	are	
currently	 used	 in	 clinical	 practice.	 As	DNA	 replication	 and	 repair	 processes	 cooperate	 to	 preserve	
genomic	 integrity,	 synthetic	 lethality	 effects	 might	 exist,	 and	 should	 be	 searched	 for,	 among	 all	
chromosome	instability	(CIN)	genes.		
A	distinctive	feature	of	metabolic	processes	such	as	DNA	replication,	repair	and	transcription	is	the	
high	degree	of	 conservation	of	 their	protein	 components	among	eukaryotes.	 This	observation	has	
recently	 been	 exploited	 to	 screen	 CIN	 genes	 in	 yeast,	 as	 a	 quick	 way	 of	 identifying	 potentially	
druggable	candidates	displaying	synthetic	lethality	with	DNA	repair	genes	that	are	often	mutated	in	
human	cancers8,9.	Such	analysis	highlighted	Ctf4	(Chromosome	Transmission	Fidelity	4)10,11	as	a	highly	
promising	 candidate,	 at	 a	 centre	 of	 a	web	 of	 negative	 genetic	 interactions	with	 other	 CIN	 genes.	
Moreover,	the	same	appears	to	be	true	for	the	human	orthologue	of	yeast	Ctf4,12.	The	high	level	of	
genetic	connections	involving	Ctf4	is	likely	to	reflect	its	known	role	as	a	protein	hub	linking	different	
processes	 pertaining	 to	 chromosome	 stability,	 such	 as	 DNA	 replication	 and	 sister	 chromatid	
cohesion13,14	(Figure	1).		
Ctf4	does	not	possess	intrinsic	enzymatic	activity	and	therefore	lacks	an	active	site,	making	it	harder	
to	target	with	traditional	small-molecule	screening	strategies.		Our	recent	work	has	elucidated	a	key	
mechanism	of	recruitment	to	Ctf4	of	its	protein	partners:	binding	is	mediated	by	a	short	linear	motif	
(SLIM)15,16,	known	as	the	Ctf4-interacting	peptide	(CIP),	which	docks	in	a-helical	form	onto	an	exposed	
site	 on	 the	 helical	 domain	 of	 Ctf4,	 fused	 to	 Ctf4’s	 second	 b-propeller	 domain	 (Figure	 1)13,14.	 The	
interaction	 is	 of	 moderate,	 micromolar	 affinity	 and	 represents	 an	 example	 of	 the	 SLIM-protein	
interactions	that	characterise	the	dynamic	architecture	of	the	replisome17.	The	determination	of	the	
structural	 basis	 for	 the	 interaction	 of	 Ctf4	with	 its	 client	 proteins	 has	 afforded	 an	 opportunity	 to	
develop	a	strategy	for	targeting	Ctf4,	by	interfering	with	its	function	as	a	protein	hub.	
Targeting	 protein-protein	 interfaces	 (PPIs)	 as	 a	 means	 of	 specifically	 disrupting	 the	 association	
between	macromolecules	would	increase	greatly	the	range	of	druggable	protein	targets,	and	a	lot	of	
effort	 has	 gone	 into	 developing	 effective	 PPI	 inhibitors18-20.	 Traditional	 small	 molecule	 library	
approaches	are	often	not	suitable	for	inhibiting	PPIs	though,	as	such	interfaces	consist	usually	of	large	
and	relatively	 flat	 surfaces.	A	promising	approach	to	generate	a-helical	PPI	 inhibitors	 is	 the	use	of	
conformationally-constrained	 peptides,	 often	 referred	 to	 as	 ‘stapled	 peptides’,	 especially	 when	
referring	to	a	peptide	constrained	 into	an	a-helical	conformation21-23.	 In	addition	to	their	potential	
value	as	 inhibitors,	stapled	peptides	represent	useful	proof-of-principle	tools	 to	 identify	 targetable	
interactions	 of	 interesting	 proteins	 with	 their	 physiological	 partners,	 and	 to	 dissect	 biological	
pathways.		
Peptide	stapling	is	a	macrocyclisation	approach	in	which	helical	peptides	are	covalently	modified	by	
the	formation	of	a	chemical	linkage	(staple)	between	side	chains	of	two	amino	acids24.	The	residues	
to	be	linked	together	are	usually	located	on	the	same	face	of	the	peptide	helix,	and	separated	by	one,	
two	or	three	helical	turns,	so	that	one	amino	acid	at	position	 i	 is	linked	to	position	 i+4,	 i+7	or	 i+11,	
respectively.	Stapling	can	constrain	a-helical	peptides	 into	their	bioactive	conformation,	 improving	
target	affinity	and	overall	pharmacokinetics25.	When	optimised,	peptide	stapling	can	generate	potent	
in	vivo	inhibitors	of	intracellular	PPI	targets26-28.	We	have	recently	pioneered	a	two	component	double-
click	stapling	technique	that	makes	use	of	double	Cu(I)-catalysed	azide-alkyne	cycloaddition	(CuAAC)	
between	diazido	peptides	with	dialkynyl	staple	linkages29,30.	This	approach	enables	a	range	of	different	
stapled	peptides	to	be	efficiently	generated	by	reacting	a	single	linear	diazido	peptide	with	a	collection	
of	different	dialkynyl	stapling	linkages	(Figure	2A).	
In	this	paper,	we	describe	the	design	of	a	stapled	peptide	targeting	the	 interaction	of	Ctf4	with	 its	
client	 proteins	 (Figure	 2B),	 based	 on	 the	 CIP	 sequence	 present	 in	 the	 GINS	 Sld5	 subunit	 of	 the	
replicative	helicase	complex	Cdc45-MCM-GINS	(CMG)13.	The	most-effective	stapled	peptide	bound	to	
Ctf4	in	the	same	fashion	as	the	wild-type	sequence,	as	determined	by	X-ray	crystallography	of	the	Sld5	
CIP	bound	to	Ctf4	C-terminal	domain	(Ctf4CTD),	but	with	about	10-fold	increased	affinity.	Interestingly,	
the	a-helix	of	the	stapled	peptide	was	conformationally	constrained	by	an	unorthodox	i,i+6	spacing;	
to	the	best	of	our	knowledge,	this	is	the	first	time	that	the	i,i+6	constraint	has	been	used	to	improve	
helical	content	and	target	binding.	Furthermore,	the	stapled	CIP	was	able	to	disrupt	the	biochemical	
interaction	between	Ctf4CTD	and	GINS	in	vitro	and	to	detach	the	Ctf4-client	DNA	polymerase	a	from	
the	 replisome	 in	 yeast	 extracts.	 Our	 study	 provides	 the	 first	 proof-of-principle	 evidence	 that	 it	 is	
possible	to	develop	chemical	tools	to	target	the	Ctf4	hub	in	the	eukaryotic	replisome.	
RESULTS	
Rationale	for	chemical	synthesis	of	stapled	peptides	
We	had	previously	 found	 that	 the	GINS	subunit	Sld5	 is	 responsible	 for	anchoring	Ctf4	 to	 the	CMG	
helicase,	and	showed	that	binding	is	mediated	by	the	interaction	of	a	short	sequence	motif	of	Sld5	
(Ctf4-interacting	 peptide	 or	 CIP;	 1-MDINIDDILAELDKETTAV-19)	 with	 an	 exposed	 site	 in	 the	 helical	
domain	of	 the	Ctf4CTD	 structure13	 (Figure	3A).	Alanine-scanning	mutagenesis	had	 revealed	 that	 the	
hydrophobic	amino	acids	I5,	I8	and	L9	at	the	binding	interface	were	critical	for	interaction	with	Ctf413.	
Keeping	 the	 key	 residues	 in	 place,	 four	 different	 stapling	 positions	 were	 designed	 into	 the	 Sld5	
sequence	by	inspection	of	the	Ctf4CTD-Sld5	complex	structure	(PDB	id:	4c95),	including	two	sequences	
with	conventional	stapling	at	i,i+7	and	two	unorthodox	i,i+6	and	i,i+8	staplings	(Figure	3B).	The	diazido-
peptides	 CF-A,	 CF-B,	 CF-C,	 CF-D	 (Figure	 3B),	 where	 ‘CF’	 represents	 N-terminal	 capping	 with	 5(6)-
carboxyfluorescein,	 were	 synthesised	 on	 Rink	 amide	 resin	 using	 automated	 solid-phase	 peptide	
synthesis.	Copper-catalysed	double-click	macrocyclisations	were	subsequently	performed	with	1,3-
diethynylbenzene	(staple	1	in	Figure	2A)	to	generate	the	corresponding	bis-triazole	stapled	peptides	
CF-A1,	CF-B1,	CF-C1	and	CF-D1.		
Fluorescence	anisotropy	of	stapled-peptide	interactions	with	the	Ctf4CTD	
The	 Sld5-based	 stapled	 peptides	 were	 first	 evaluated	 for	 their	 ability	 to	 bind	 Ctf4CTD	 in	 vitro	 in	 a	
fluorescence	anisotropy	(FP)	assay,	using	peptides	that	had	been	N-terminally	labelled	with	carboxy-
fluorescein	(CF).	The	i,i+6	stapled	peptide	A1	displayed	a	stronger	binding	affinity	for	Ctf4CTD	(Kd	=	0.84	
±	0.19	μM)	compared	to	the	wild-type	peptide	Sld51-19	(Kd	=	3.5	±	0.2	μM),	whereas	the	i,i+7	stapled	
peptides	B1	and	C1	(Kd	=	18	±	1	and	6.4	±0.6	µM	respectively)	and	the	i,i+8	peptide,	D1,	showed	weaker	
binding	to	Ctf4	(Kd	=	15	±	1	µM)	(Figure	4A	and	Table	1).	
As	 the	Sld5	peptide	A1,	stapled	at	positions	 i,	 i+6,	 showed	 the	 strongest	binding	 to	Ctf4CTD,	 it	was	
further	 investigated	 using	 our	 divergent	 double-click	 stapling	 strategy	 to	 explore	 different	 staple	
scaffolds.	The	stapled	peptide	A2,	which	bears	a	linear	aliphatic	staple	linkage	(staple	2	in	Figure	2A),	
was	able	to	bind	to	Ctf4CTD	with	a	Kd	of	0.32	±	0.02	µM	(Figure	4B,	Table	1	and	Supplementary	figure	
1).	Alternative	aliphatic	staples	3	and	4	(Figure	2A)	were	also	investigated:	the	corresponding	stapled	
peptides	A3	and	A4	bound	to	Ctf4	with	comparable	Kd	values	of	1.3	µM,	better	than	the	wild-type	
peptide	but	not	as	tight	as	A2	(Figure	4B).	However,	the	linkers	in	A3	and	A4	provide	attachment	points	
for	 chemical	 derivatisation	 of	 the	 staple	 which	 could	 be	 exploited	 for	 instance	 to	 improve	 cell	
permeabilization26,28,	while	 still	 retaining	dissociation	constants	 that	are	2.7-fold	 stronger	 than	 the	
wild-type	peptide.		
FP	analysis	of	A2	showed	that	 its	binding	to	Ctf4CTD	was	one	order	of	magnitude	stronger	than	the	
wild-type	 peptide	 (Sld51-19).	 To	 confirm	 this	 improvement	 in	 the	 binding	 strength	 to	 Ctf4,	 we	
performed	a	competition	experiment	using	CF-A2	peptide	bound	to	Ctf4CTD,	and	competed	off	 the	
fluorescently-labelled	peptide	with	unlabelled	Sld51-19	or	A2	peptides	 (Figure	4C).	 The	 competition	
experiment	showed	that	A2	peptide	is	a	better	competitor	for	Ctf4	binding	(apparent	Kd	=	0.18	µM)	
than	the	wild-type	Sld51-19	peptide	(apparent	Kd	=	7.7	µM).	
Stapling	of	the	Sld5	CIP	increases	its	intrinsic	a-helical	nature	
In	the	crystal	structure	of	Ctf4CTD	bound	to	the	Sld5	CIP,	the	peptide	adopts	a	two-turn	a-helical	fold13	
(Figure	3A).	We	set	out	to	investigate	whether	the	Sld5	CIP	is	intrinsically	unfolded	in	solution,	and	
whether	stapling	might	promote	a-helical	structure	 in	the	A2	peptide	that	could	explain	 its	higher	
affinity	for	Ctf4.	Circular	dichroism	(CD)	analysis	of	Sld51-19	and	A2	peptides	 indicated	that	they	are	
largely	 unfolded	 in	 aqueous	buffer	 (Figure	5),	 and	 that	 addition	of	 tri-fluoroethanol	 (TFE)	 induced	
partial	a-helix	 formation	 in	 both	 peptides,	 as	 expected	 (inset	 in	 Figure	 5).	 In	 the	 absence	 of	 TFE	
however,	we	noticed	a	significant	difference	in	a-helical	content	between	the	two	peptides:	whereas	
the	wild-type	Sld5	peptide	is	only	7%	helical,	the	a-helix	content	of	A2	is	21%,	three	times	higher	than	
wild-type.	Conversely,	the	CD	analysis	of	the	diazido-peptide	A,	the	modified	peptide	prior	to	double-
click	chemistry,	suggests	that	its	helical	content	is	only	3%.	Thus,	it	is	reasonable	to	assume	that	the	
physical	linkage	between	i	and	i+6	residues	in	the	A2	peptide	is	responsible	for	its	higher	intrinsic	α-
helical	content,	which	would	account	for	its	stronger	binding	to	Ctf4.		
Crystal	structure	of	the	stapled	Sld5	CIP	bound	to	Ctf4CTD	
To	determine	whether	the	mode	of	binding	of	A2	to	Ctf4CTD	was	as	originally	observed	in	the	Ctf4CTD	-	
Sld5	CIP	structure13	and	to	elucidate	the	conformation	of	the	stapled	Sld5	peptide	bound	to	Ctf4CTD,	
we	determined	the	X-ray	crystal	structure	of	the	Ctf4CTD	-	A2	complex,	by	soaking	the	stapled	peptide	
in	crystals	of	Ctf4CTD	(Figure	6).	The	experiment	showed	that	the	A2	CIP	binds	Ctf4CTD	in	an	identical	
way	to	the	wild-type	Sld5	CIP,	with	no	significant	difference	in	peptide	conformation.	Interestingly,	a	
reproducible	improvement	in	diffraction	properties	of	the	Ctf4CTD	crystals	was	observed	upon	soaking	
of	the	A2	peptide,	which	provides	further,	indirect	evidence	that	A2	has	a	stronger	affinity	for	Ctf4CTD	
than	the	wild-type	Sld5	CIP.	In	the	structure,	the	linear	aliphatic	bis-triazole	linker	is	located	on	the	
opposite	 side	 of	 the	 A2	 peptide	 relative	 to	 the	 Sld5	 CIP	 -	 Ctf4CTD	 interface,	 thus	 achieving	 the	
conformation	that	had	originally	been	planned.	As	such,	the	linker	is	fully	exposed	to	solvent	and	must	
therefore	attain	its	higher	affinity	by	facilitating	the	adoption	of	the	correct	helical	conformation	for	
Ctf4CTD	binding	via	 its	stapling	effect.	The	structure	further	shows	that	the	triazole	ring	proximal	to	
stapling	 position	 i	 packs	 against	 the	 salt	 link	 between	 Sld5	 D7	 and	 Ctf4	 R904,	 providing	 further	
stabilisation	of	the	Sld5	CIP	-	Ctf4CTD	interface.		
The	Sld5	CIP	achieves	a	partial	disruption	of	the	GINS	-	Ctf4CTD	complex	
We	next	investigated	the	ability	of	the	wild-type	Sld5	CIP	and	its	stapled	version	A2	to	interfere	with	
the	interaction	between	GINS	and	Ctf4CTD.	For	this	experiment,	increasing	amounts	of	peptide	were	
incubated	with	reconstituted	Ctf4CTD	-	GINS	complex	and	the	samples	were	analysed	by	analytical	gel	
filtration	 (Figure	 7).	 The	 chromatographs	 were	 normalised	 and	 the	 relative	 ratios	 in	 peak	 height	
between	GINS	and	the	GINS	-	Ctf4CTD	complex	were	calculated	as	described	in	the	methods	(Figure	7A	
and	7B,	inset).	Addition	of	both	wild-type	Sld5	and	stapled	A2	peptide	caused	a	partial	disruption	of	
the	Ctf4CTD	-	GINS	complex	in	a	concentration-dependent	manner,	as	demonstrated	by	the	reduction	
in	peak	size	for	the	Ctf4CTD	-	GINS	complex	and	increase	in	the	amount	of	free	GINS.	The	disruptive	
effect	of	the	Sld5	CIP	peptides	was	noticeable	but	limited;	the	incomplete	dissociation	of	the	complex	
is	 in	 agreement	with	 previous	 evidence	 indicating	 that	 the	 interaction	 surface	 between	GINS	 and	
Ctf4CTD	extends	beyond	the	Sld5-CIP	binding	site13.	Nevertheless,	at	the	highest	concentration	tested	
in	the	assay,	the	stapled	peptide	A2	was	nearly	twice	more	efficient	than	the	wild-type	Sld5	CIP.		
The	Sld5	CIP	displaces	a	Ctf4	client	from	the	replisome	in	yeast	cell	extracts	
Our	previous	work	showed	that	the	CIP	of	Pol1,	the	catalytic	subunit	of	yeast	DNA	polymerase	a	(Pol	
a), is	required	for	Pol1	to	associate	with	Ctf4	in	vitro13.	Moreover,	mutations	in	the	Pol1	CIP	lead	to	
displacement	of	Pol	a	from	the	replisome	in	yeast	cells13.	To	explore	whether	it	is	possible	to	develop	
inhibitors	of	the	interaction	of	Ctf4	with	clients	such	as	Pol1,	we	assayed	the	ability	of	the	stapled	or	
natural	versions	of	the	Sld5	CIP	to	disrupt	the	association	of	Pol	a	with	the	replisome	 in	yeast	cell	
extracts.		After	synchronising	budding	yeast	cells	in	S-phase	(Figure	8A),	cell	extracts	were	generated	
and	 incubated	with	 or	 without	 Sld5-CIP	 or	 control	 peptides,	 before	 isolation	 of	 the	 replisome	 by	
immunoprecipitation	of	a	tagged	version	of	the	Sld5	subunit	of	the	CMG	helicase	(Figure	8B).		Whereas	
none	of	the	peptides	disrupted	the	CMG	helicase	or	its	interactions	with	partners	such	as	Csm3,	the	
Sld5	CIP	peptides	specifically	displaced	Pol	a	from	the	replisome.		Notably,	stapled	A2	version	of	the	
Sld5	 CIP	 was	more	 effective	 at	 lower	 concentrations	 than	 the	 wild-type	 Sld5	 CIP	 (Figure	 8B).	 	 In	
contrast	 to	 the	 complete	disruption	 achieved	 for	 the	 association	of	 Pol	a	with	 the	 replisome,	 the	
stapled	version	of	the	Sld5	CIP	had	a	more	modest	effect	on	the	association	of	Ctf4	with	the	CMG	
helicase	(Figure	8B).		This	is	consistent	with	our	past	data	showing	that	mutation	of	the	Sld5	CIP	does	
not	displace	Ctf4	 from	CMG13,	presumably	 reflecting	 the	more	extensive	nature	of	 the	 interaction	
between	Ctf4	and	CMG.		Correspondingly,	the	Sld5	CIP	was	only	partially	able	to	displace	Ctf4	from	
the	GINS	component	of	the	CMG	helicase	in	vitro	(Figure	5),	though	the	stapled	A2	peptide	showed	
two-fold	greater	efficacy	than	the	natural	Sld5	CIP.		Nevertheless,	these	data	indicate	that	the	stapled	
Sld5	CIP	can	efficiently	inhibit	the	association	of	replisome-bound	Ctf4	with	client	proteins	such	as	Pol	
a.	
Discussion	
The	experiments	described	here	provide	proof-of-principle	evidence	that	it	is	possible	to	disrupt	Ctf4’s	
function	in	the	replisome,	by	interfering	with	its	ability	to	associate	with	CIP-box	containing	partner	
proteins	 such	 as	 Pol	a.	 This	 has	 been	 achieved	 by	 the	 structure-based	 design	 of	 Ctf4-interacting	
peptides	that	include	a	staple	linker	for	stabilisation	and	improved	affinity.	We	have	shown	the	design	
and	biochemical	validation	of	one	such	stapled	peptide,	A2,	which	contains	the	CIP	sequence	of	the	
helicase	subunit	GINS	Sld5,	modified	with	a	linear,	aliphatic	bis-triazole	staple	linking	positions	N4	and	
A10	of	the	wild-type	Sld5	sequence.	The	stapled	A2	peptide	displays	a	higher	affinity	towards	Ctf4CTD	
than	the	wild-type	sequence	by	about	one	order	of	magnitude,	and	is	more	effective	at	interfering	
with	Ctf4	function,	as	determined	by	biochemical	experiments	with	purified	protein	components	and	
in	yeast	extracts.		
The	 A2	 peptide	 displayed	 limited	 take-up	 in	 yeast	 cells	 (F.V.	 and	 K.L.,	 unpublished	 data	 with	
fluorescent	versions	of	A2	generated	by	Y.W.	and	D.R.S.),	which	prevented	us	from	assessing	its	ability	
to	interfere	with	Ctf4	function	in	vivo.	However,	the	method	allows	for	a	simple	approach	to	garner	
cell	permeability	by	modification	of	the	staple26,28.	Future	work	will	be	required	to	fully	explore	the	
potential	 of	 stapled	 peptides	 to	 inhibit	 Ctf4	 function	 in	 cells	 and	 tissues,	 perhaps	 by	 systematic	
derivatisation	of	the	stapling	group,	which	is	facilitated	by	our	two-component	double-click	stapling	
technique.	Furthermore,	our	proof-of-concept	work	with	 stapled	peptides	will	 serve	 to	 inspire	 the	
development	of	small-molecule	inhibitors	with	different	pharmacological	properties.		
The	role	of	Ctf4	as	a	hub	in	the	replisome,	coupling	DNA	synthesis	to	diverse	molecular	processes	that	
pertain	 to	chromosome	replication	and	segregation,	 is	 likely	 to	be	conserved	 in	diverse	eukaryotic	
species.	 For	 example,	 the	 human	 orthologue	 of	 Ctf4	 (also	 known	 as	 AND-1	 or	 WDHD1)	 shares	
sequence	conservation,	domain	structure,	oligomerisation	status	and	physiological	roles	with	its	yeast	
orthologue.	It	is	therefore	likely	that	human	CTF4	will	represent	an	attractive	therapeutic	target	in	the	
treatment	of	cancers	carrying	defects	in	CIN	genes,	and	our	work	raises	the	prospect	that	it	will	be	
possible	to	design	inhibitors	of	the	interaction	of	human	CTF4	with	its	client	proteins.	Future	efforts	
will	 be	 devoted	 to	 developing	 appropriate	 strategies,	 including	 the	 stapled-peptide	 approach	
demonstrated	here,	to	target	the	biochemical	function	of	CTF4	in	human	cells.	As	the	type	of	peptide-
protein	 interaction	 involving	Ctf4	and	 its	partner	proteins	 is	 likely	 to	 represent	a	paradigm	for	 the	
dynamic	functional	architecture	of	the	replisome,	such	an	approach	might	also	be	applicable	to	other	
instances	of	PPI	between	components	of	the	human	replisome.	
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The	coordinates	and	structure	factors	for	the	crystal	structure	of	Ctf4CTD	bound	to	the	A2	peptide	have	
been	deposited	in	the	Protein	Data	Bank	under	accession	number	5NXQ.	
Figure	Legend	
Figure	1.	The	drawing	summarises	our	current	understanding	of	Ctf4	function	in	the	eukaryotic	
replisome,	as	a	protein	hub	connecting	replisome	components	such	as	the	DNA	helicase	CMG	and	
DNA	polymerase	a,	as	well	as	other	factors	such	as	the	Dna2	helicase-nuclease	and	the	Chl1	
helicase.	The	oval	inset	shows	a	ribbon	representation	of	the	Ctf4CTD	trimer	in	purple,	with	bound	
CIPs	as	yellow	cylinders.	
Figure	2.	A	Double-click	peptide	stapling.	The	diazido-peptide	is	combined	with	different	dialkynyl	
staples	under	CuI	catalysis	to	obtain	several	bis-triazole	stapled	peptides.	B	Drawing	illustrating	the	
mechanism	of	targeting	with	stapled	CIPs	the	interface	of	the	Ctf4	trimer	with	its	client	proteins.		
	
Figure	3.	A	Two	views	of	the	Ctf4CTD	-	Sld5	CIP	interface	(PDB	ID	4c95).	B	Sequence	of	the	wild-type	
Sld5	CIP	and	of	the	A,	B,	C	and	D	peptides.	The	stapling	positions	in	each	peptide	are	marked	as	X	(all	
X	=	Orn(N3)).	The	stapling	positions	of	the	A,	B,	C	and	D	peptides	are	also	shown	mapped	onto	the	
the	structure	of	the	Sld5	CIP	bound	to	Ctf4CTD,	in	four	separate	panels.	
Figure	4.	Fluorescence	polarisation	(FP)	measurements	of	the	affinity	of	stapled	Sld5	CIPs	towards	
Ctf4CTD.	A	FP	binding	curves	for	stapled	peptide	A1	to	B1,	differing	in	stapling	position.	B	FP	binding	
curves	for	Sld5	CIPs	stapled	at	i,	i+6,	in	order	to	test	different	staple	scaffolds.	C	FP	competition	
experiment	between	wild-type	Sld5	CIP	and	the	stapled	A2	peptide.		
Figure	5.	Circular	dichroism	(CD)	analysis	of	wild-type	Sld5	and	stapled	A2	CIPs.	The	CD	spectra	were	
recorded	in	the	presence	of	0,	15	and	30%	tri-fluoroethanol	(TFE).	
Figure	6.	X-ray	crystal	structure	of	Ctf4CTD	bound	to	the	A2	peptide.	A	Close-up	view	of	the	A2	
peptide	structure,	highlighting	the	position	of	the	linear	aliphatic	bis-triazole	linker.	The	stapling	
positions	i	and	i+6	are	indicated	by	arrows.	The	final	2Fo	–	Fc	electron	density	map	contoured	at	1s	
for	the	refined	crystallographic	model	is	shown	as	a	transparent	surface,	superimposed	on	the	
structure.	B	Superposition	of	the	structure	of	Ctf4CTD	bound	to	the	stapled	A2	peptide	and	the	wild-
type	Sld5	CIP	(PDB	id	4c95).	Ctf4CTD	is	shown	as	a	light-brown	ribbon,	and	the	CIP	peptides	are	drawn	
as	sticks,	in	cyan	(A2	peptide)	and	light	sea	green	(Sld5	peptide).	
Figure	7.	Gel	filtration	assays	measuring	the	ability	of	wild-type	Sld5	and	A2	CIPs	to	disrupt	the	
Ctf4CTD	-	GINS	complex.	The	data	was	normalised	relative	to	the	total	area	under	the	combined	peaks	
and	expressed	as	the	ratio	of	the	GINS	complex	peak	height	to	Ctf4CTD	-	GINS	complex	peak	height	
(insets).	A	Experiments	performed	in	the	presence	of	wild-type	Sld5	CIP.	B	Experiments	performed	in	
the	presence	of	the	A2	peptide.	
Figure	8.	The	Sld5	CIP	displaces	Pol	a	from	the	replisome	in	yeast	cell	extracts.	A	TAP-SLD5	budding	
yeast	cells	(YSS47)	were	grown	at	30 °C,	arrested	in	G1	phase	with	mating	pheromone,	and	then	
released	into	S	phase	for	20 minutes.	DNA	content	was	measured	by	flow	cytometry.		B	The	TAP-
tagged	Sld5	subunit	of	the	CMG	helicase	was	then	isolated	from	cell	extracts	by	
immunoprecipitation	in	presence	of	the	indicated	stapled	peptides	or	controls	(the	peptides	were	all	
dissolved	in	DMSO),	and	the	indicated	proteins	were	detected	by	immunoblotting	with	the	
corresponding	antibodies.	
	
Supplementary	Figure	Legend	
Supplementary	figure	1.	Fluorescence	polarisation	(FP)	measurements	of	the	affinity	of	stapled	Sld5	
CIPs	CF-A1	and	CF-A2	towards	Ctf4CTD.		
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Table	1.	Binding	affinities	of	Sld5	peptides	for	Ctf4CTD	
	 Peptide		 Kd	(μM)	
	
CF-Sld51-19	
	
3.5	±	0.2	
	 	
CF-A1	 0.75	±	0.03	
CF-B1	 18	±	1	
CF-C1	 6.4	±	0.6	
CF-D1	 15	±	1	
	 	
CF-A2	 0.37	±	0.01	
CF-A3	 1.3	±	0.2	
CF-A4	 1.3	±	0.1	
  
Table	2.		Data	collection	and	refinement	statistics	
Wavelength	 	
Resolution	range	 49.21		-	2.413	(2.499		-	2.413)	
Space	group	 P	2	21	21	
Unit	cell	 88.679	100.287	219.749	90	90	90	
Total	reflections	 1003177	(90575)	
Unique	reflections	 76177	(7499)	
Multiplicity	 13.2	(12.1)	
Completeness	(%)	 99.96	(99.83)	
Mean	I/sigma(I)	 14.80	(1.03)	
Wilson	B-factor	 58.96	
R-merge	 0.1424	(2.453)	
R-meas	 0.1482	(2.563)	
R-pim	 0.04074	(0.7354)	
CC1/2	 0.999	(0.329)	
CC*	 1	(0.703)	
Reflections	used	in	refinement	 76170	(7499)	
Reflections	used	for	R-free	 3805	(365)	
R-work	 0.1804	(0.3461)	
R-free	 0.2108	(0.3733)	
CC(work)	 0.969	(0.644)	
CC(free)	 0.968	(0.565)	
Number	of	non-hydrogen	atoms	 9971	
		macromolecules	 9552	
		ligands	 60	
		solvent	 359	
Protein	residues	 1181	
RMS(bonds)	 0.003	
RMS(angles)	 0.59	
Ramachandran	favored	(%)	 96.26	
Ramachandran	allowed	(%)	 3.30	
Ramachandran	outliers	(%)	 0.43	
Rotamer	outliers	(%)	 0.19	
Clashscore	 2.11	
Average	B-factor	 67.98	
		macromolecules	 68.08	
		ligands	 97.55	
		solvent	 60.43	
Statistics	for	the	highest-resolution	shell	are	shown	in	parentheses.	
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